Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis

@article{Pedersen2018EfficacyOA,
  title={Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis},
  author={Niels C Pedersen and Yunjeong Kim and Hongwei Liu and Anushka C Galasiti Kankanamalage and Chrissy Eckstrand and William C. Groutas and Michael J Bannasch and Juliana M Meadows and Kyeong-Ok Chang},
  journal={Journal of Feline Medicine and Surgery},
  year={2018},
  volume={20},
  pages={378 - 392}
}
Objectives The safety and efficacy of the 3C-like protease inhibitor GC376 was tested on a cohort of client-owned cats with various forms of feline infectious peritonitis (FIP. [...] Key Method Results Nineteen of 20 cats treated with GC376 regained outward health within 2 weeks of initial treatment. However, disease signs recurred 1–7 weeks after primary treatment and relapses and new cases were ultimately treated for a minimum of 12 weeks.Expand
Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis
TLDR
GS-441524 was shown to be a safe and effective treatment for FIP and the optimum dosage was found to be 4.0 mg/kg SC q24h for at least 12 weeks. Expand
Current status on treatment options for feline infectious peritonitis and SARS-CoV-2 positive cats
TLDR
An update on the current status of therapeutics for FIP is provided and due to interest in coronaviruses resulting from the current human pandemic, this review provides information on domesticated cats identified as SARS-CoV-2 positive. Expand
In Vivo Antiviral Effects of U18666A Against Type I Feline Infectious Peritonitis Virus
TLDR
When U18666A was administered to cats experimentally infected with type I FIPV, the development of FIP might be suppressed compared with the control group, however, the number of animals with FIP is too low to establish anti-viral effect of U18 666A in cats. Expand
Therapeutic effect of an anti-human-TNF-alpha antibody and itraconazole on feline infectious peritonitis
TLDR
The combined use of adalimumab and ICZ showed a therapeutic effect for experimentally induced FIP and are considered to be a treatment option until effective anti-FIPV drugs become available. Expand
Clinical efficacy of combination therapy of itraconazole and prednisolone for treating effusive feline infectious peritonitis
TLDR
In conclusion, itraconazole partly exerted a beneficial effect in a cat with FIP, however, further investigation of a possible role of itraconsazole in FIP treatment is warranted. Expand
Antiviral treatment using the adenosine nucleoside analogue GS‐441524 in cats with clinically diagnosed neurological feline infectious peritonitis
TLDR
Four cases of naturally occurring FIP with CNS involvement were treated with the antiviral nucleoside analogue GS‐441524 and may result in clearance and long‐term resolution of neurological FIP. Expand
In Vitro Effects of Doxycycline on Replication of Feline Coronavirus
TLDR
It is suggested that doxycycline has some inhibitory effect on FIPV replication in vitro, which supports future clinical trials of its use for the treatment of FIP-affected cats. Expand
A rational approach to identifying effective combined anticoronaviral therapies against feline coronavirus
Feline infectious peritonitis (FIP), caused by a genetic mutant of feline enteric coronavirus known as FIPV, is a highly fatal disease of cats with no currently available vaccine or FDA-approvedExpand
Possible Antiviral Activity of 5-Aminolevulinic Acid in Feline Infectious Peritonitis Virus (Feline Coronavirus) Infection
TLDR
The study suggested that 5-ALA is applicable for the treatment and prevention of FIPV infection and evaluated its antiviral activity against FipV in felis catus whole fetus-4 cells and feline primary macrophages. Expand
Protease inhibitor GC376 for COVID-19: Lessons learned from feline infectious peritonitis
TLDR
Since both GC373 and GC376 have already been successfully used in treating animal coronavirus infection, they can be considered as strong drug candidates for COVID-19 in humans and developed framework for their use in human trials. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 28 REFERENCES
Polyprenyl Immunostimulant Treatment of Cats with Presumptive Non-Effusive Feline Infectious Peritonitis In a Field Study
TLDR
Treatment with Polyprenyl Immunostimulant shows promise in the treatment of dry form FIP, but a controlled study will be needed to verify the benefit. Expand
Levels of feline infectious peritonitis virus in blood, effusions, and various tissues and the role of lymphopenia in disease outcome following experimental infection
TLDR
The effect of lymphopenia on disease outcome was reconfirmed and FIPV genomic RNA was found to be highly macrophage associated within diseased tissues and effusions as determined by RT-qPCR and immunohistochemistry but was not present in blood. Expand
An update on feline infectious peritonitis: Virology and immunopathogenesis
TLDR
After a half century, FIP remains one of the last important infections of cats for which there is no single diagnostic test, no vaccine and no definitive explanations for how virus and host interact to cause disease. Expand
Effect of Polyprenyl Immunostimulant on the survival times of three cats with the dry form of feline infectious peritonitis
TLDR
Three cats with dry form FIP were treated with Polyprenyl Immunostimulant and two of the three cats are still on treatment and are alive and well 2 years after diagnosis. Expand
Pathogenesis of feline enteric coronavirus infection
TLDR
Fifty-one specific pathogen-free (SPF) cats 10 weeks to 13 years of age were infected with a cat-to-cat fecal–oral passed strain of feline enteric coronavirus (FECV), and kittens born to experimentally infected project queens began shedding virus spontaneously, but never before 9–10 weeks of age. Expand
Diagnostic Features of Clinical Neurologic Feline Infectious Peritonitis
TLDR
Most cats with neurologic and ocular forms of FIP had patchy, focal lesions, suggesting that recently developed technologies described in this report may be useful for evaluation of cats with suspected FIP. Expand
The influence of age and genetics on natural resistance to experimentally induced feline infectious peritonitis
TLDR
Exposure to non-FIP-inducing feline coronaviruses prior to challenge with virulent FIPV did not significantly affect FIP incidence but did accelerate the disease course in some cats. Expand
Broad-Spectrum Inhibitors against 3C-Like Proteases of Feline Coronaviruses and Feline Caliciviruses
TLDR
The results suggest that the series of 3CLpro inhibitors described here may have the potential to be further developed as therapeutic agents against these important viruses in domestic and wild cats and provide the first insight into a structural platform for anti-FIPV and anti-FCV drug development. Expand
Potent inhibition of feline coronaviruses with peptidyl compounds targeting coronavirus 3C-like protease
TLDR
It is reported that these compounds behave as reversible, competitive inhibitors of 3CL protease, potently inhibited the replication of feline coronaviruses (EC50 in a nanomolar range) and, furthermore, combination of cathepsin B and 3 CL protease inhibitors led to a strong synergistic interaction against feline coroneruses in a cell culture system. Expand
A review of feline infectious peritonitis virus infection: 1963–2008
  • N. Pedersen
  • Medicine
  • Journal of Feline Medicine & Surgery
  • 2009
TLDR
F eline infectious peritonitis (FIP) was first described as an ‘important disorder of cats’ by Holzworth in 1963 and a clinico-pathologic conference on this disorder was published in the following year. Expand
...
1
2
3
...